Jounce Therapeutics - JNCE Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" JNCE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in JNCE, but not buy additional shares or sell existing shares.
View JNCE analyst ratings or view top-rated stocks.

5 brokerages have issued 1-year price targets for Jounce Therapeutics' stock. Their JNCE share price forecasts range from $3.00 to $11.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 294.7% from the stock's current price.
View analysts price targets for JNCE or view top-rated stocks among Wall Street analysts.

Jounce Therapeutics' stock was trading at $1.11 on January 1st, 2023. Since then, JNCE shares have increased by 36.9% and is now trading at $1.52.
View the best growth stocks for 2023 here.

Jounce Therapeutics saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 4,170,000 shares, an increase of 202.2% from the February 13th total of 1,380,000 shares. Based on an average trading volume of 2,390,000 shares, the short-interest ratio is presently 1.7 days. Currently, 9.6% of the shares of the company are sold short.
View Jounce Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our JNCE earnings forecast.

Jounce Therapeutics, Inc. (NASDAQ:JNCE) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by $0.15. During the same period in the prior year, the company posted ($0.73) earnings per share.

45 employees have rated Jounce Therapeutics Chief Executive Officer Richard Murray Ph.D on Glassdoor.com. Richard Murray Ph.D has an approval rating of 97% among the company's employees. This puts Richard Murray Ph.D in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Exelixis (EXEL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), CRISPR Therapeutics (CRSP), Novavax (NVAX), Mylan (MYL), Progenics Pharmaceuticals (PGNX), Adaptimmune Therapeutics (ADAP), Incyte (INCY) and Nektar Therapeutics (NKTR).

(JNCE) raised $76 million in an initial public offering (IPO) on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

Jounce Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Bank of America Corp DE (6.34%), Millennium Management LLC (3.54%), Morgan Stanley (3.21%), Dimensional Fund Advisors LP (1.38%), Geode Capital Management LLC (1.30%) and Assenagon Asset Management S.A. (1.01%). Insiders that own company stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kevin C Tang, Kimberlee C Drapkin, Richard /Ca/ Murray, Rock Ventures Ii LP Third and Rock Ventures Iii LP Third.
View institutional ownership trends.

Shares of JNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of JNCE stock can currently be purchased for approximately $1.52.

Jounce Therapeutics (NASDAQ:JNCE) has a market capitalization of $79.25 million and generates $82 million in revenue each year. The company earns $-50,920,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis.

The company employs 137 workers across the globe.

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.jouncetx.com. The company can be reached via phone at (857) 259-3840 or via email at mdeon@jouncetx.com.